Treatment of a feline cutaneous mast cell tumour using imatinib mesylate as a neoadjuvant tyrosine kinase inhibitor therapeutic agent J., Kim H. (2020): Treatment of a feline cutaneous mast cell tumour using imatinib mesylate as a neoadjuvant tyrosine kinase inhibitor therapeutic agent. Veterinarni Medicina, 65: 84-88.
download PDF

A two-year-old spayed female American shorthair cat presented with a rough, circular, exophytic mass on the genital area. The clinical findings and histopathological examination revealed that the mass contained neoplastic mast cells and, thus, was diagnosed as a mast cell tumour. The anatomical location of the mass was not easily accessible for surgical intervention. We administered a targeted therapy using oral imatinib mesylate for eight weeks to reduce the size of the lesion and to facilitate the successful surgical removal. The tumour mass eventually reduced by 21% and was surgically excised. This is possibly the first study to use imatinib mesylate as a tumour reduction neoadjuvant to therapeutically address a feline cutaneous mast cell tumour located in a surgically inaccessible part of the body.

Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 2009 Jan;45(2):228-47.
Halsey CHC, Powers BE, Kamstock DA. Feline intestinal sclerosing mast cell tumour: 50 cases (1997–2008). Vet Comp Oncol. 2010 Mar;8(1):72-9.
Isotani M, Tamura K, Yagihara H, Hikosaka M, Ono K, Washizu T, Bonkobara M. Identification of a c-kit exon 8 internal tandem duplication in a feline mast cell tumour case and its favorable response to the tyrosine kinase inhibitor imatinib mesylate. Vet Immunol Immunopathol. 2006 Nov;114(1-2):168-72.
Isotani M, Ishida N, Tominaga M, Tamura K, Yagihara H, Ochi S, Kato R, Kobayashi T, Fujita M, Fujino Y, Setoguchi A, Ono K, Washizu T, Bonkobara M. Effect of tyrosine kinase inhibition by imatinib mesylate on mast cell tumours in dogs. J Vet Intern Med. 2008 Jul-Aug;22(4):985-8.
Isotani M, Yamada O, Lachowicz JL, Tamura K, Yagihara H, Fujino Y, Ono K, Washizu T, Bonkobara M. Mutations in the fifth immunoglobulin-like domain of kit are common and potentially sensitive to imatinib mesylate in feline mast cell tumours. Br J Haematol. 2010 Jan;148(1):144-53.
London CA, Thamm DH. Mast cell tumours. In: Withrow SJ, Vail DM, Page RL, editors. Small animal clinical oncology. 5th ed. Philadelphia, US: Elsevier; 2012. p. 335-55.
Marconato L, Bettini G, Giacoboni C, Romanelli G, Cesari A, Zanelli A, Zini E. Clinicopathological features and outcome for dogs with mast cell tumours and bonemarrow involvement. J Vet Intern Med. 2008 Jul-Aug;22(4):1001-7.
Sabattini S, Bettini G. Prognostic value of histologic immunohistochemical features in feline cutaneous mastcell tumours. Vet Pathol. 2010 Jul;47(4):643-53.
Simpson AM, Ludwig LL, Newman SJ, Bergman PJ, Hottinger HA, Patnaik AK. Evaluation of surgical margins required for complete excision of cutaneous mast cell tumours in dogs. J Am Vet Med Assoc. 2004 Jan;24(2):236-40.
Stanclift RM, Gilson SD. Evaluation of neoadjuvant prednisone administration and surgical excision in treatment of cutaneous mast cell tumors in dogs. J Am Vet Med Assoc. 2008 Jan;232(1):53-62.
Takeuchi Y, Fujino Y, Fukushima K, Watanabe M, Nakagawa T, Ohno K, Sasaki N, Sugano S, Tsujimoto H. Biological effect of tyrosine kinase inhibitors on three canine mast cell tumour cell lines with various KIT statuses. J Vet Pharmacol Ther. 2012 Feb;35(1):97-104.
download PDF

© 2022 Czech Academy of Agricultural Sciences | Prohlášení o přístupnosti